Načítá se...
Delayed adverse events in phase I trials of molecularly targeted and cytotoxic agents
BACKGROUND: Grade 3 and 4 adverse events (AEs) during cycle 1 are traditionally used for dose escalation decisions in Phase I oncology trials. With molecularly targeted agents (MTAs), assessment of lower grade AEs and those in later cycles is considered increasingly relevant. METHODS: We conducted a...
Uloženo v:
| Vydáno v: | Oncotarget |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Impact Journals LLC
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6188052/ https://ncbi.nlm.nih.gov/pubmed/30338038 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26104 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|